Vimarsana
Biggest News Aggregation in the World

Page 19 - Merck Sharp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Merck Sharp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Merck Sharp Today - Breaking & Trending Today

Cervical cancer | Government to encourage vaccination of girls in age group of 9-14 years against cervical cancer - Vimarsana News

Cervical cancer | Government to encourage vaccination of girls in age group of 9-14 years against cervical cancer

Union Minister Nirmala Sitharaman made this announcement while presenting the Union interim Budget 2024-2025 in Parliament

Financial Analysis: Earth Science Tech (OTCMKTS:ETST) versus NGM Biopharmaceuticals (NASDAQ:NGM) - Vimarsana News

Financial Analysis: Earth Science Tech (OTCMKTS:ETST) versus NGM Biopharmaceuticals (NASDAQ:NGM)

Earth Science Tech (OTCMKTS:ETST – Get Free Report) and NGM Biopharmaceuticals (NASDAQ:NGM – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, institutional ownership and earnings. Institutional and Insider Ownership 58.1% of […]

Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance - Vimarsana News

Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance

2023 Sets Stage for Future Growth Potential: Completed Seagen Acquisition, Creating World-Class Oncology Organization; Launched Significant Number of New Products and Indications; and Realigned...

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 - Vimarsana News

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126

Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced data from its ...

Immunotherapy post-surgery improves overall s - Vimarsana News

Immunotherapy post-surgery improves overall s

<p>For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer.&nbsp;&ldquo;We can now tell our patients that pembrolizumab after surgery not only delays recurrences but also helps them live longer,&rdquo; said the study&rsquo;s lead investigator <a href="https://www.dana-farber.org/find-a-doctor/toni-choueiri">Toni Choueiri, MD</a>, of <a href="https://www.dana-farber.org/">Dana-Farber Cancer Institute<...